VISTA H-Score Is Significantly Associated with a 5-Year DFS Rate in Oral Squamous Cell Carcinoma

Oral squamous cell carcinoma (OSCC) is the most common type of oral cancer in the world. Despite its prevalence, it is often recognized in advanced stages (III or IV) when it has already spread to local lymph nodes. In this study, we investigate the V-domain Ig suppressor of T cell activation (VISTA) as a potential prognostic factor in OSCC. Tissue samples were collected from 71 oral squamous cell carcinoma patients to determine protein expression levels (using immunochemistry and the semi-quantitative H-score method). Moreover, RT-qPCR was additionally performed in 35 patients. Clinical factors in our cohort study had no impact on VISTA expression. However, VISTA expression is largely correlated with Il-33 levels in tumor cells and lymphocytes and with PD-L1 in tumor cells. The impact of VISTA expression on overall survival (OS) is rather limited, but in the case of a 5-year survival rate, a significant association has been proven. VISTA seems to be a rather weak clinicopathological marker but needs further evaluation in the context of survival. In addition, the potential of VISTA combination with Il-33 or PD-L1 should be further investigated in OSCC.

[1]  M. Karkouri,et al.  The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis , 2021, Scientific Reports.

[2]  G. Marvaso,et al.  High PD-L1 Expression on Tumor Cells Indicates Worse Overall Survival in Advanced Oral Squamous Cell Carcinomas of the Tongue and the Floor of the Mouth but Not in Other Oral Compartments , 2021, Biomedicines.

[3]  H. Atreya,et al.  PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy , 2021, Communications biology.

[4]  A. Starzyńska,et al.  ZNF-281 as the Potential Diagnostic Marker of Oral Squamous Cell Carcinoma , 2021, Cancers.

[5]  Chen Zhao,et al.  Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy , 2021, Cancers.

[6]  Q. Sun,et al.  VISTA Expression on Immune Cells Correlates With Favorable Prognosis in Patients With Triple-Negative Breast Cancer , 2021, Frontiers in Oncology.

[7]  A. Quaas,et al.  LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma—Potential Biomarkers for Targeted Therapy Concepts , 2020, International journal of molecular sciences.

[8]  F. Ghiringhelli,et al.  Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency , 2020, Cancers.

[9]  Yuanyuan Zhou,et al.  Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer , 2020, Journal of Cancer Research and Clinical Oncology.

[10]  Zhaohui Lu,et al.  High VISTA Expression Correlates With a Favorable Prognosis in Patients With Colorectal Cancer , 2020, Journal of immunotherapy.

[11]  Xing Huang,et al.  VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy , 2020, Journal of Hematology & Oncology.

[12]  Qunxing Li,et al.  Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis , 2020, Scientific Reports.

[13]  E. Schaafsma,et al.  VISTA: Coming of age as a multi‐lineage immune checkpoint , 2020, Clinical and experimental immunology.

[14]  Jie Chen,et al.  VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer , 2019, Cancer Immunology, Immunotherapy.

[15]  T. Zander,et al.  The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma , 2019, Oncoimmunology.

[16]  N. Matsumura,et al.  VISTA expressed in tumour cells regulates T cell function , 2018, British Journal of Cancer.

[17]  W. Wen,et al.  Stromal interleukin-33 promotes regulatory T cell-mediated immunosuppression in head and neck squamous cell carcinoma and correlates with poor prognosis , 2018, Cancer Immunology, Immunotherapy.

[18]  S. Mineishi,et al.  VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML , 2018, Oncoimmunology.

[19]  J. Fisher,et al.  VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival , 2018, Cancer Immunology, Immunotherapy.

[20]  Li-xu Yan,et al.  VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma , 2018, BMC Cancer.

[21]  L. Ding,et al.  A novel stromal lncRNA signature reprograms fibroblasts to promote the growth of oral squamous cell carcinoma via LncRNA-CAF/interleukin-33 , 2018, Carcinogenesis.

[22]  R. Herbst,et al.  Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.

[23]  J. Wilmott,et al.  Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients , 2017, Modern Pathology.

[24]  I. Wistuba,et al.  VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer , 2017, Nature Medicine.

[25]  Chao Cheng,et al.  Immunoregulatory functions of VISTA , 2017, Immunological reviews.

[26]  L. Ni,et al.  New checkpoints in cancer immunotherapy , 2017, Immunological reviews.

[27]  Lei Wu,et al.  Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma , 2017, Cancer Immunology, Immunotherapy.

[28]  R. Noelle,et al.  A New VISTA on combination therapy for negative checkpoint regulator blockade , 2016, Journal of Immunotherapy for Cancer.

[29]  M. Azuma,et al.  Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma. , 2016, Oral oncology.

[30]  Halli E. Miller,et al.  Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses , 2015, Proceedings of the National Academy of Sciences.

[31]  L. Sempere,et al.  VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy , 2014, Cancer Immunology Research.

[32]  Lieping Chen,et al.  Coinhibitory receptor PD-1H preferentially suppresses CD4⁺ T cell-mediated immunity. , 2014, The Journal of clinical investigation.

[33]  David C. Gondek,et al.  VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses , 2011, The Journal of experimental medicine.